Role of Antioxidants in the Prevention of Cancer

Journal of Experimental and Clinical Medicine

Volumn 4, Issue 4, 2012, Pages 215-222

  Bennett, Lunawati L ^a   Rojas, Stephen ^b   Seefeldt, Teresa ^c  

^a UNION UNIVERSITY   (United States)

^b PALM BEACH ATLANTIC UNIVERSITY   (United States)

^c SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Antioxidants; Cancer; Dietary supplement; Malignant disorder; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CAROTENOID; CATECHIN; DIMETHYLXANTHENONE 4 ACETIC ACID; EPIGALLOCATECHIN GALLATE; FLAVANOL DERIVATIVE; FLAVONOID; ISOFLAVONE DERIVATIVE; PLACEBO; RESVERATROL; RETINOL; SELENIUM; SELENOMETHIONINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; CLINICAL TRIAL (TOPIC); COLON TUMOR; COLORECTAL CANCER; DIET SUPPLEMENTATION; DIETARY INTAKE; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS TUMOR; FRUIT; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HEART PROTECTION; HUMAN; IN VITRO STUDY; INTESTINE TUMOR; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MEDLINE; METABOLIC DISORDER; NAIL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON MELANOMA SKIN CANCER; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SELENOSIS; SOFT TISSUE CANCER; STOMACH CANCER; VEGETABLE;

EID: 84865761086     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2012.06.001     Document Type: Review

References (149)

1. American Cancer Society. Cancer Facts and Figures 2012. [accessed 13.07. 2012].
2. World Health Organization. Fact Sheet. [accessed 13.07. 2012].
3. Jemal A., Siegel R., Ward E. Cancer statistics. Cancer J Clin 2008, 58:71-96.
4. Klaunig J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004, 44:239-267.
5. Glade M.J. Food, nutrition, and the prevention of cancer: a global perspective. Nutrition 1999, 15:523-526.
6. Evans J.L. Antioxidants: do they have a role in the treatment of insulin resistance?. Indian J Med Res 2007, 125:355-372.
7. Kowluru R.A., Chan P.S. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007, 43603.
8. Franco R., Schoneveld O., Georgakilas A.G. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 2008, 266:6-11.
9. Khan N., Afaq F., Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 2008, 10:475-510.
10. Valko M., Leibfritz D., Moncol J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
11. Reuter S., Gupta S.C., Chaturvedi M.M. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med 2010, 49:1603-1616.
12. Hail N., Cortes M., Drake E.N., Spallholz J.E. Cancer chemoprevention: a radical perspective. Free Radic Biol Med 2008, 45:97-110.
13. Fairweather-Tait S.J., Bao Y., Broadley M.R., Colling R., Ford D., Hesketh J., Hurst R. Selenium in human health and disease. Antioxid Redox Signal 2011, 14:1337-1383.
14. Zhang W., Joseph E., Hitchcock C., DiSilvestro R.A. Selenium glycinate supplementation increases blood glutathione peroxidase activities and decreases prostate-specific antigen readings in middle-aged US men. Nutr Res 2011, 31:165-168.
15. Arner E.S.J., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000, 267:6102-6109.
16. Dennert G., Zwahlen M., Brinkman M. Selenium for preventing cancer. Cochrane Database Syst Rev 2011, 5:CD005195.
17. Ledesma M.C., Jung-Hynes B., Schmit T.L., Kumar R., Mukhtar H., Ahmad N. Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med 2011, 17:134-143.
18. Sarveswaran S., Liroff J., Zhou Z., Nikitin A., Ghosh J. Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: implication for the treatment of early-stage prostate cancer. Int J Oncol 2010, 36:1419-1428.
19. Dong Y., Ganther H.E., Stewart C., Ip C. Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 2002, 62:708-714.
20. Venkateswaran V., Klotz L.H., Fleshner N.E. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002, 62:2540-2545.
21. Reagan-Shaw S., Nihal M., Ahsan H., Mukhtar H., Ahmad N. Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate 2008, 68:1624-1634.
22. Yang H., Fang J., Jia X.D., Han C., Chen X.X., Yang C.S., Li N. Chemopreventive effects of early-stage and late-stage supplementation of vitamin E and selenium on esophageal carcinogenesis in rats maintained on a low vitamin E/selenium diet. Carcinogenesis 2011, 32:381-388.
23. Ip C., Lisk D.J. Efficacy of cancer prevention by high-selenium garlic is primarily dependent on the action of selenium. Carcinogenesis 1995, 16:2649-2652.
24. Ip C., Lisk D.J., Thompson H.J. Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis 1996, 17:1979-1982.
25. Finley J.W., Davis C.D., Feng Y. High selenium from broccoli protects rats from colon cancer. J Nutr 2000, 130:2384-2389.
26. Burke K.E., Clive J., Combs G.F., Nakamura R.M. Effects of topical L-selenomethionine with topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. J Am Acad Dermatol 2003, 49:458-472.
27. Waters D.J., Shen S., Cooley D.M., Bostwick D.G., Qian J., Combs G.F., Glickman L.T., et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 2003, 95:237-241.
28. Venkateswaran V., Fleshner N.E., Sugar L.M., Klotz L.H. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004, 64:5891-5896.
29. Bjorkhem-Bergman L., Torndal U.B., Eken S., Nystrom C., Capitanio A., Larsen E.H., Bjornstedt M., et al. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis 2005, 26:125-131.
30. Kandas N.O., Randolph C., Bosland M.C. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutr Cancer 2009, 61:251-264.
31. Ozten N., Horton L., Lasano S., Bosland M.C. Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model. Cancer Prev Res (Phila) 2010, 3:371-380.
32. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., Minasian L.M., et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). J Am Med Assoc 2011, 306:1549-1556.
33. Clark L.C., Combs G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., Davis L.S., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA 1996, 276:1957-1963.
34. Clark L.C., Dalkin B., Krongrad A., Combs G.F., Turnbull B.W., Slate E.H., Witheington R., et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998, 81:730-734.
35. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., Parnes H.L., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009, 301:39-51.
36. Duffield-Lillico A.J., Slate E.H., Reid M.E., Turnbull B.W., Wilkins P.A., Combs G.F., Park H.K., et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003, 95:1477-1481.
37. Kline K., Lawson K.A., Yu W., Sanders B.G. Vitamin E and cancer. Vitam Horm 2007, 76:435-461.
38. Li G.X., Lee M.J., Liu A.N.B., Yang Z.H., Lin J., Shih W.C.J., Yang C.S. Delta-tocopherol is more active than alpha- or gamma-tocopherol in inhibiting lung tumorigenesis in vivo. Cancer Prev Res (Phila) 2011, 4:404-413.
39. Liu H.K., Wang Q., Li Y., Sun W.G., Liu J.R., Yang Y.M., Xu W.L. Inhibitory effects of gamma-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells. J Nutr Biochem 2010, 21:206-213.
40. Fernandes N.V., Guntipalli P.K., Mo H.B. d-{Delta}-tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells. Anticancer Res 2010, 30:4937-4944.
41. Riedel S.B., Fischer S.M., Sanders B.G., Kline K. Vitamin E analog, alpha-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice. Anticancer Drugs 2008, 19:175-181.
42. Rahman S., Bhatia K., Khan A.Q., Kaur M., Ahmad F., Rashid H., Athar M., et al. Topically applied vitamin E prevents massive cutaneous inflammatory and oxidative stress responses induced by double application of 12-O-tetradecanoylphorbol-13-acetate (TPA) in mice. Chem Biol Interact 2008, 172:195-205.
43. Jiang Q., Wong J., Ames B.N. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via caspase-dependent and independent mechanisms. Ann N Y Acad Sci 2004, 1031:399-400.
44. Calvisi D.F., Ladu S., Hironaka K., Factor V.M., Thorgeirsson S.S. Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer. J Hepatol 2004, 41:815-822.
45. Zhang Y., Ni J., Messing E.M., Chang E., Yang C.R., Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A 2002, 99:7408-7413.
46. Venkateswaran V., Fleshner N.E., Klotz L.H. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002, 168:1578-1582.
47. Factor V.M., Laskowska D., Jensen M.R., Woitach J.T., Popescu N.C., Thorgeirsson S.S. Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci U S A 2000, 97:2196-2201.
48. Bravi F., Polesel J., Bosetti C., Talamini R., Negri E., Dal Maso L., Serraino D., et al. Dietary intake of selected micronutrients and the risk of pancreatic cancer: an Italian case-control study. Ann Oncol 2011, 22:202-206.
49. Berton T.R., Conti C.J., Mitchell D.L., Aldaz C.M., Lubet R.A., Fischer S.M. The effect of vitamin E acetate on ultraviolet-induced mouse skin carcinogenesis. Mol Carcinog 1998, 23:175-184.
50. Gensler H.L., Aickin M., Peng Y.M., Xu M. Importance of the form of topical vitamin E for prevention of photocarcinogenesis. Nutr Cancer 1996, 26:183-191.
51. van Lee L., Heyworth J., McNaughton S., Iacopetta B., Clayforth C., Fritschi L. Selected dietary micronutrients and the risk of right- and left-sided colorectal cancers: a case-control study in Western Australia. Ann Epidemiol 2011, 21:170-177.
52. Hotaling J.M., Wright J.L., Pocobelli G., Bhatti P., Porter M.P., White E. Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the vitamins and lifestyle study. J Urol 2011, 185:1210-1215.
53. Ezzedine K., Latreille J., Kesse-Guyot E., Galan P., Hereberg S., Guinot C., Malvy D. Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer 2010, 46:3316-3322.
54. Kirsh V.A., Hayes R.B., Mayne S.T., Chatterjee N., Subar A.F., Dixon L.B., Albanes D. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006, 98:245-254.
55. Albanes D., Heinonen O.P., Huttunen J.K., Taylor P.R., Virtamo J., Edwards B.K., Haapakoski J. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995, 62(Suppl. 6):S1427-S1430.
56. Heinonen O.P., Albanes D., Virtamo J., Taylor P.R., Huttunen J.K., Hartman A.M., Haapakoski J., et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440-446.
57. Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., Ross C., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005, 293:1338-1347.
58. Gaziano J.M., Glynn R.J., Christen W.G., Kurth T., Belanger C., NacFadyen J., Bubes V., et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009, 301:52-62.
59. Lin J., Cook N.R., Albert C., Zaharris E., Gaziano J.M., Van Denburgh M., Buring J.E., et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 2009, 101:14-23.
60. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029-1035. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group.
61. Sesso H.D., Buring J.E., Christen W.G., Kurth T., Belanger C., MacFadyen J., Bubes V., et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008, 300:2123-2133.
62. Rock C.L. Carotenoids: biology and treatment. Pharmacol Ther 1997, 75:185-197.
63. Paiva S.A., Russell R.M. Beta-carotene and other carotenoids as antioxidants. J Am Coll Nutr 1999, 18:426-433.
64. Johnson E.J. The role of carotenoids in human health. Nutr Clin Care 2002, 5:56-65.
65. Sampaio A.R.D., Chagas C.E.A., Ong T.P. Vitamin A and beta-carotene inhibitory effect during 1,2-dimethylhydrazine induced hepatocarcinogenesis potentiated by 5-azacytidine. Food Chem Toxicol 2007, 45:563-567.
66. Palozza P., Serini S., Maggiano N., Angelini M., Boninsegna A., DiNicuolo F., Ranelletti F., et al. Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by beta-carotene through down-regulation of cyclin A and Bcl-2 family proteins. Carcinogenesis 2002, 23:11-18.
67. Temple N.J., Basu T.K. Protective effect of beta-carotene against colon tumors in mice. J Natl Cancer Inst 1987, 78:1211-1214.
68. Alabaster O., Tang Z., Frost A., Shivapurkar N. Effect of beta-carotene and wheat bran fiber on colonic aberrant crypt and tumor formation in rats exposed to azoxymethane and high dietary fat. Carcinogenesis 1995, 16:127-132.
69. Ziegler R.G. A review of epidemiologic evidence that carotenoids reduce the risk of cancer. J Nutr 1989, 119:116-122.
70. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150-1155.
71. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B., Cook N.R., Belanger C., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334:1145-1149.
72. Greenberg E.R., Baron J.A., Stukel T.A., Stevens M.M., Mandel J.S., Spencer S.K., Elias P.M., et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990, 323:789-795.
73. Liu H.L., Jiang W.B., Xie M.X. Flavonoids: recent advances as anticancer drugs. Recent Pat Anticancer Drug Discov 2010, 5:152-164.
74. Yao H., Xu W., Shi X., Zhang Z. Dietary flavonoids as cancer prevention agents. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2011, 29:1-31.
75. Prasad S., Phromnoi K., Yadav V.R., Chaturvedi M.M., Aggarwal B.B. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 2010, 76:1044-1063.
76. Jaganathan S.K. Can flavonoids from honey alter multidrug resistance?. Med Hypotheses 2011, 76:535-537.
77. Rossi M., Bosetti C., Negri E., Lagiou P., LaVecchia C. Flavonoids, proanthocyanidins, and cancer risk: a network of case-control studies from Italy. Nutr Cancer 2010, 62:871-877.
78. Rossi M., Rosato V., Bosetti C. Flavonoids, proanthocyanidins, and the risk of stomach cancer. Cancer Causes Control 2010, 21:1597-1604.
79. Gonzalez-Gallego J., Garcia-Mediavilla M.V., Sanchez-Campos S., Tunon M.J. Fruit polyphenols, immunity and inflammation. Br J Nutr 2010, 104(Suppl. 3):S15-S27.
80. Katiyar S.K. Green tea prevents non-melanoma skin cancer by enhancing DNA repair. Arch Biochem Biophys 2011, 508:152-158.
81. Hou D.X., Kumamoto T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid Redox Signal 2010, 13:691-719.
82. Jomova K., Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology 2011, 283:65-87.
83. Crowley-Weber C.L., Dvorakova K., Crowley C., Bernstein H., Bernstein C., Garewal H., Payne C.M. Nicotine increases oxidative stress, activates NF-kappaβ and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stress by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis. Chem Biol Interact 2003, 145:53-56.
84. Wu C.H., Lee C.H., Ho Y.S. Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res 2011, 17:3533-3541.
85. Shin V.Y., Wu W.K., Ch K.M., Wong H.P., Lam E.K., Tai E.K., Koo M.W., et al. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol Cancer Res 2005, 3:607-615.
86. D'hoedt D., Bertrand D. Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin Ther Targets 2009, 13:395-411.
87. Ching S.L., Min H.P. Mechanism of possible chemopreventive effects of natural dietary compounds on smoking-induced tumorigenesis. J Exp Clin Med 2011, 3:262-271.
88. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66:1234-1240.
89. Büchner F.L., Bueno-de-Mesquita H.B., Ross M.M. Consumption of vegetables and fruit and the risk of bladder cancer in the European prospective investigation into cancer and nutrition. Int J Cancer 2009, 125:2643-2651.
90. Khan N., Adhami V.M., Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Canc 2010, 17:R39-R52.
91. Mukherjee S., Dudley J.I., Das D.K. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010, 8:478-500.
92. Bradamante S., Barenghi L., Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev 2004, 22:169-188.
93. Wang Q., Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., Sun G.Y., Sun A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002, 958:439-447.
94. Sinha K., Chaudhary G., Gupta Y.K. Properties effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 2002, 71:655-665.
95. Vingtdeux V., Dresses-Werringloer U., Zhao H., Davies P., Marambaud P. Therapeutic potential in resveratrol in Alzheimer's disease. BMC Neurosci 2008, 9(Suppl. 2):S6.
96. Ungvari Z., Orosz Z., Rivera A. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007, 292:H2417-H2424.
97. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
98. Soleas G.J., Grass L., Josephy P.D. A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin Biochem 2006, 39:492-497.
99. Whitsett T.G., Lamartiniere C.A. Genistein and resveratrol: mammary cancer chemoprevention and mechanisms of action in the rat. Expert Rev Anticancer Ther 2006, 6:1699-1706.
100. Manna S.K., Mukhopadhayay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappaβ, activator protein-1, and apoptosis potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164:6509-6519.
101. Benitez D.A., Hermoso M.A., Pozo-Guisado E. Regulation of cell survival by resveratrol involves inhibition of NF kappa β-regulated gene expression in prostate cancer cells. Prostate 2009, 69:1045-1054.
102. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007, 224:274-283.
103. Li Z.G., Hong T., Shimada Y., Komoto I., Kawabe A., Ding Y., Kaganoi J., et al. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 2002, 23:1531-1536.
104. Banerjee S., Bueso-Ramos C., Aggarwal B.B. Suppression of 7,12-dimethylbenzanthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κβ, cycloxgenase 2, and matrix metalloprotease 9. Cancer Res. 2002, 62:4945-4954.
105. Garvin S., Ollinger K., Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 2006, 231:113-122.
106. Gill C., Walsh S.E., Morrissey C. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007, 67:1641-1653.
107. Narayanan B.A., Narayanan N.K., Re D.D. Differential expression of genes induced by resveratrol in LNCaP cells: p53-mediated molecular targets. Int J Cancer 2003, 104:204-212.
108. Aziz M.H., Nihal M., Fu V.X., Jarrad D.F., Ahmad N. Resveratrol caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phophatidylinositol 3'-kinase/Akt pathway and BCl-2 family proteins. Mol Cancer Ther 2006, 5:1335-1341.
109. Ma X., Tian X., Huang X., Yan F., Qiao D. Resveratrol induced mitochondrial dysfunction and apoptosis are associated with Ca2+ and mCICR-mediated MPT activation in HepG2 cells. Mol Cell Biochem 2007, 302:99-109.
110. Sun Z.J., Pan C.E., Liu H.S., Wang G.J. Anti-hepatoma activity of resveratrol in vitro. World J Gastroenterol 2002, 8:79-81.
111. Carbo N., Costelli P., Baccino F.M. Resveratrol: a natural product present in wine, decreases tumor growth in a rat tumor model. Biochem Biophys Res Commun 1999, 254:739-743.
112. Ding X.Z., Adrian T.E. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 2002, 25:e71-e76.
113. Kubota T., Uemura Y., Kobayashi M., Taguchi H. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res 2003, 23:403-446.
114. LeCorre L., Fustier P., Chalabi N. Effects of resveratrol on expression of panel of genes interacting with the BRCA1 onco-suppressor in human breast cancer lines. Clin Chim Acta 2004, 344:115-121.
115. Wang Y., Lee K.W., Chan F.L., Shiuan C., Leung L.K. The red wine polyphenol resveratrol displays bi-level inhibition of aromatase in breast cancer cells. Toxicol Sci 2006, 92:71-77.
116. Hy Y., Sun C.Y., Huang J., Hong L., Zhang L., Chu Z.B. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J 2007, 120:1672-1677.
117. Kovacic P., Somanathan R. Multifaceted approach to resveratrol bioactivity focus on antioxidant action, cell signaling and safety. Oxid Med Cell Longev 2010, 3:86-100.
118. Gao S., Liu G.Z., Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 2004, 59:214-225.
119. Miura T., Muraoka S., Fujimoto Y. Inactivation of creatine kinase induced by stilbene derivatives. Pharmacol Toxicol 2002, 90:66-72.
120. Galati G., Sabzevari O., Wilson J.X. Prooxidant activity and cellular effects of the phenoxy radicals of dietary flavanoids and other polyphenolics. Toxicology 2002, 177:91-104.
121. Athar M., Back J.H., Kopelovich L. Multiple molecular targets of resveratrol: anti-carcinogenic mechanism. Arch Biochem Biophys 2009, 486:95-102.
122. Filomeni G., Graziani I., Rotilio G. Trans-resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr 2007, 2:295-305.
123. Fremont L., Belguendouz L., Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 1999, 64:2511-2521.
124. Bhat K.P., Pezzuto J.M. Resveratrol exhibits cytostatic antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res 2001, 61:6137-6144.
125. Dong H.H., Ren H.L. New progression in the study of protective properties of resveratrol in anticardiovascular disease. Britisl Lek Listy 2004, 105:225-229.
126. Aggarwal B.B., Shishodia S., Sandur S.K. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 2006, 72:1605-1621.
127. Lee K.W., Lee H.J. The roles of polyphenols in cancer chemoprevention. Biofactors 2006, 26:105-121.
128. Penumathsa S.V., Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 2009, 87:275-286.
129. Xi J., Wang H., Mueller R.A., Norfleet E.A., Xu Z. Mechanism of resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase beta and mitochondrial permeability transition pore. Eur J Pharmacol 2009, 604:111-116.
130. Das S., Alagappan V.K., Bagchi D. Coordinated induction of iNOS-VGR-KDR-eNOAS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 2005, 42:281-289.
131. Kaga S., Zhan L., Matsumoto M. Resveratrol enhances neovascularization in the infracted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1, and vascular endothelial growth factor. J Mol Cell Cardiol 2005, 39:813-822.
132. Patel K.R., Scott E., Brown V.A., Gescher A.J., Steward W.P. Clinical trials of resveratrol. Ann N Y Acad Sci 2011, 1215:161-169.
133. Hoshino J., Park E.J., Kondratyuk T.P. Selective synthesis and biological evaluation of sulfa-conjugated resveratrol metabolites. J Med Chem 2010, 53:5033-5043.
134. Calamini B., Ratia K., Mallkowski M.G. Pleiotropic mechanism facilitated by resveratrol and its metabolites. Biochem J 2010, 429:273-282.
135. Patel K.R., Brown V.A., Jones D.J.L. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010, 70:7392-7399.
136. Brown V.K., Patel K.R., Viskaduraki M., Crowell J.A., Perloff M., Booth T.D., Vasilinin G., et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010, 70:9003-9011.
137. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003, 36:79-87.
138. Meng X., Maliakal P., Lu H., Lee M.J., Yang C.S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004, 52:935-942.
139. Walle T., Hsieh F., DeLegge M.F. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377-1382.
140. Urpi-Sarda M., Jauregui O., Raventos R.M. Uptake of diet resveratrol into the human low density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem 2005, 77:3149-3155.
141. Vitaglione P.S., Sforza S., Galaverna G. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005, 49:495-504.
142. Burton A., Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008, 52:549-557.
143. Ortuno J., Covas M.J., Farre M. Matrix effects on the bioavailability of resveratrol in humans. Food Chem 2010, 120:1123-1130.
144. Boocock D.J., Faust G.E.S., Patel K.R. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007, 16:1246-1252.
145. Nunes T., Almeida L., Rocha J.F., Falcoa A., Fernandes-Lopes C., Loureiro A.L., Wright L., et al. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 2009, 49:1477-1482.
146. Kennedy D.O., Whitman E.L., Reay J.L., Lietz G., Okello E.J., Wilde A., Haskell C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in human: a double blind placebo-controlled, crossover investigation. Am J Clin Nutr 2010, 91:1590-1597.
147. Almeida L., Vaz-da-Silva M., Falcao A. Pharmacokinetic and safety profile of trans resveratrol in a rising multiple dose study in healthy volunteers. Mol Nutr Food Res 2009, 53(Suppl. 1):S7-S15.
148. Chow H.H.S., Garland L.L., Hsu C.H., Vining D.R., Chew W.M., Miller J.A., Perloff M., et al. Resveratrol modulates drug and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 2010, 3:1168-1175.
149. Zamora-Ros R., Urpi-Sarda M., Lamuela-Raventos R.M., Estruch R., Vazquez-Agell M., Serrano-Martinez M., Jaeger W., et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 2006, 52:1373-1380.